Characteristics of 483 patients with newly diagnosed MM
| Characteristic . | n (%) . |
|---|---|
| Male sex | 281 (58) |
| Age at diagnosis, y | |
| Median | 66 |
| Range | 31-95 |
| Follow-up, y | |
| Median | 6.1 |
| Range | 0.1-15.3 |
| OS, y | |
| Median | 6.4 |
| 95% CI | 5.9-7.2 |
| PFS, y | |
| Median | 2.4 |
| 95% CI | 2.1-2.6 |
| R-ISS | |
| I | 95 (20) |
| II | 319 (66) |
| III | 69 (14) |
| FISH | |
| HR by FISH | 121 (25) |
| Del(17p)/monosomy 17 | 66 (14) |
| Dele(13q)/monosomy 13 | 232 (48) |
| Gain 1q | 101(25) |
| t(4;14) | 54 (11) |
| t(14;16) | 17 (4) |
| t(14;20) | 1 (1) |
| t(11;14) | 93 (19) |
| Hyperdiploid | 63 (13) |
| Metaphase cytogenetics | |
| Abnormal karyotype | 108 (22) |
| Del(17p)/monosomy 17 | 15 (3) |
| Del(13q)/monosomy 13 | 47 (10) |
| Gain 1q | 44 (9) |
| Hypodiploid | 16 (3) |
| Near diploid | 32 (7) |
| Hyperdiploid | 58 (12) |
| Nonhyperdiploid | 50 (10) |
| Near triploid | 2 (1) |
| Near tetraploid | 5 (1) |
| PCPro ≥2% | 92 (19) |
| First-line treatment | |
| IMiD monotherapy | 313 (65) |
| PI monotherapy | 119 (25) |
| Combined IMiD/PI | 51 (10) |
| ASCT | 137 (28) |
| Characteristic . | n (%) . |
|---|---|
| Male sex | 281 (58) |
| Age at diagnosis, y | |
| Median | 66 |
| Range | 31-95 |
| Follow-up, y | |
| Median | 6.1 |
| Range | 0.1-15.3 |
| OS, y | |
| Median | 6.4 |
| 95% CI | 5.9-7.2 |
| PFS, y | |
| Median | 2.4 |
| 95% CI | 2.1-2.6 |
| R-ISS | |
| I | 95 (20) |
| II | 319 (66) |
| III | 69 (14) |
| FISH | |
| HR by FISH | 121 (25) |
| Del(17p)/monosomy 17 | 66 (14) |
| Dele(13q)/monosomy 13 | 232 (48) |
| Gain 1q | 101(25) |
| t(4;14) | 54 (11) |
| t(14;16) | 17 (4) |
| t(14;20) | 1 (1) |
| t(11;14) | 93 (19) |
| Hyperdiploid | 63 (13) |
| Metaphase cytogenetics | |
| Abnormal karyotype | 108 (22) |
| Del(17p)/monosomy 17 | 15 (3) |
| Del(13q)/monosomy 13 | 47 (10) |
| Gain 1q | 44 (9) |
| Hypodiploid | 16 (3) |
| Near diploid | 32 (7) |
| Hyperdiploid | 58 (12) |
| Nonhyperdiploid | 50 (10) |
| Near triploid | 2 (1) |
| Near tetraploid | 5 (1) |
| PCPro ≥2% | 92 (19) |
| First-line treatment | |
| IMiD monotherapy | 313 (65) |
| PI monotherapy | 119 (25) |
| Combined IMiD/PI | 51 (10) |
| ASCT | 137 (28) |
Percentages reflect the entire cohort of 483 patients, with the exception of FISH gain 1q, for which only 405 patients had data available.
ASCT, autologous hematopoietic stem cell transplantation.